Muridda provides clients with in vivo pharmacokinetic and toxicokinetic data of pharmaceuticals, as well as formulation development and screening for vehicles during drug discovery and preclinical stages.
Test compounds include small-molecule drugs, peptides, nucleosides and nucleotides, cell therapy products, gene therapy products, and various biological macromolecules.
Experimental animals cover a wide range of species, including mice, rats, guinea pigs, rabbits, minipigs, dogs and monkeys, meeting all animal requirements for preclinical drug research and development.
Detection methods include LC-MS/MS(n), RT-PCR, ELISA and radiolabeling (Iodine-125).
Study Contents
Mass Balance Study
- Collection of various tissues and organs
- Metabolic cages for short-term and long-term housing
- Conventional or radiolabeled studies (I-125)
Quantitative Tissue Distribution Study: Detection of Drug Distribution in Major Organs and Tissues
- QWBA (to be launched soon)
- Conventional methods: tissue collection and isolation, total radioactivity detection, LC-MS/MS detection / QPCR detection
Drug Excretion: Analysis of Drug Excretion Rates in Urine, Feces and Bile
- Biliary excretion
- Rat model
- Bile duct cannulation technique
Metabolism studies: metabolite identification, qualitative or quantitative analysis
- Metabolite identification using LC-MS(n) analysis
- Analysis of urine, feces, plasma and bile samples
Special Administration Routes
- Intravenous infusion
- Capsule administration in rats
- Intratracheal administration
- Gastrointestinal site-specific delivery
Special Animal Models
- Hepatic portal vein cannulation model
- Bile duct cannulation model